AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04493333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Dehydroepiandrosterone
Description: This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
Study NCT06250426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pre-thickened oral nutritional supplement without a cooling sensation flavour
Description: Pre-thickened oral nutritional supplement (ONS) drink without cooling sensation flavour
Study NCT04493333 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Polycarbophil Moisturizer
Description: This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
Study NCT04710303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
Study NCT06307366 — intervention group
Intervention type: OTHER
Intervention: No intervention will be used
Description: This is a qualitative study, no intervention will be used
Study NCT06570265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBR membrane
Description: GBR procedure is a technique often used in conjunction with dental implants to enhance the success and stability of the implant. This technique involves using barrier membranes to protect the bone graft or defect site from the rapid proliferation of surrounding soft tissues. In this clinical investigation resorbable, collagen membrane will be used.
Study NCT04486677 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caring Cards Group
Description: Group of Veteran card-makers.
Study NCT04486677 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caring Cards Recipients
Description: Group of Veteran card-recipients.
Study NCT04876391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study NCT06381622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
Study NCT06381622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
Study NCT06381622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine
Description: 20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)
Study NCT06381622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
Study NCT06320366 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: The TMS Cool-B65 A/P coil on its placebo side delivers electrical stimulation to the scalp (e.g., mimicking sensations associated with real stimulation) but does not provide magnetic stimulation to the targeted cortical structure.
Study NCT06320366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TMS
Description: The TMS Cool-B65 A/P coil delivers magnetic stimulation to targeted cortical structure.
Study NCT06452706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC).
Study NCT06041880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive calf muscle stretching device
Description: Modified night splints will be used to passive stretch the calf muscle.
Study NCT04703751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter
Description: Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
Study NCT05492448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
Study NCT05492448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. salivarius AP-32 and L. reuteri GL-104
Description: Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
Study NCT05492448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri GL-104
Description: Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.
Study NCT04912063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) Infusion
Study NCT04912063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection or Intravenous (IV) Injection/Infusion
Study NCT04912063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet
Study NCT05746143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate 10 mg
Description: two days preoperatively and five days postoperatively
Study NCT05746143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two days preoperatively and five days postoperatively
Study NCT05361408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid, once
Description: Intravenous infusion of 5mg zoledronic acid, once
Study NCT05361408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid, twice
Description: Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
Study NCT06334146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tap dance program
Description: Participants will take part in a weekly adapted tap dance class, for one hour per week, for eight weeks.
Study NCT05254509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Occupational therapy helps individuals with chronic pain to participate in daily activities in an adaptive way. The subjects will be provided with customized plans and objectives to address their self-care, vocational, and leisure goals. This includes education, home exercises, stress management, home safety, energy conservation, and work simplification - all of which promote a safe return to daily activities.
Study NCT05254509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy +Virtual Reality
Description: The occupational therapy +VR utilizes the regular therapy sessions along with providing a Virtual reality headset to relieve pain. After each VR session, there will be a debriefing from the therapist.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.
Study NCT06431373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib PO QD
Description: Brepocitinib PO QD
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other
Description: Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments.
Study NCT06423261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002 Recombinant Peptide Inhalation Solution
Description: Inhalation administration
Study NCT06423261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhalation administration
Study NCT05740280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCP-NI
Description: 20 mg/mL iCP-NI solution for intravenous injection
Study NCT05740280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for intravenous injection
Study NCT05866523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team Based Inpatient ARTAS
Description: Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.
Study NCT05866523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subject admitted and seen by routine inpatient medical service.
Study NCT06431373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO QD
Description: Placebo PO QD
Study NCT04713657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: N-thymidine
Description: 15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
Study NCT04713657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: N-thymidine
Description: 15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
Study NCT04713657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Urine Collection
Description: Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
Study NCT04713657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urine Collection
Description: Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
Study NCT04713657 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiogram
Description: On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in ToF/PS and is non-invasive.
Study NCT04713657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in ToF/PS and is non-invasive.
Study NCT04713657 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac MRI
Description: A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle.
Study NCT04713657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle.
Study NCT04713657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Hydrochloride
Description: For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
Study NCT04713657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
Study NCT04713657 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Exam
Description: On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
Study NCT04713657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exam
Description: On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
Study NCT04713657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Specimen Collection
Description: On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
Study NCT04713657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specimen Collection
Description: On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
Study NCT06692023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
Study NCT06692023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
Study NCT06692023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
Study NCT06692023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
Study NCT05109520 — intervention group
Intervention type: DRUG
Intervention: Insulin Glargine 300 UNT/ML [Toujeo]
Description: Switch during standard routine care to Gla-300.
Study NCT06692959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 vaccine IMU-201 (PD1-Vaxx)
Description: Investigational Medicinal Product (IMP) PD1-Vaxx is supplied as lyophilized drug substance APi2568, which is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (G-P-S-L). IMU-201 is combined with water for Injection (WFI) and is emulsified with Montanide ISA 51 VG adjuvant to produce PD1-Vaxx.
Study NCT06723821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation group
Description: During the 12 sessions of which the treatment consists in applying 60 minutes of microcurrent in low intensity.
Study NCT06723821 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuromodulation sham group
Description: During the 12 sessions of which the treatment consists in applying 60 minutes of sham microcurrent in low intensity.
Study NCT06157060 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: circulating tumor DNA
Description: blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma